Three US Food and Drug Administration-approved therapies for chronic GVHD

被引:46
作者
Zeiser, Robert [1 ]
Lee, Stephanie J. [2 ,3 ]
机构
[1] Univ Freiburg, Dept Med 1, Med Ctr, Fac Med, Freiburg, Germany
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA USA
[3] Univ Washington, Dept Med, Seattle, WA USA
基金
美国国家卫生研究院;
关键词
VERSUS-HOST-DISEASE; CONSENSUS DEVELOPMENT PROJECT; CLINICAL-TRIALS; CRITERIA; IBRUTINIB; RUXOLITINIB; PREVENTION; DIAGNOSIS; MURINE; IV;
D O I
10.1182/blood.2021014448
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic graft-versus-host disease ( cGVHD) is a major immunologic complication of allogeneic hematopoietic cell transplantation. cGVHD involves multiple organs, reduces quality of life, and often requires prolonged therapy with glucocorticoids, causing severe side effects. After 4 decades of testing multiple therapeutic approaches, ibrutinib, belumosudil, and ruxolitinib were US Food and Drug Administration approved for cGVHD in the last 4 years. Here we put a spotlight on their mechanisms of action, studies that led to approval, and their future role in cGVHD.
引用
收藏
页码:1642 / 1645
页数:4
相关论文
共 35 条
[1]   CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease [J].
Alexander, Kylie A. ;
Flynn, Ryan ;
Lineburg, Katie E. ;
Kuns, Rachel D. ;
Teal, Bianca E. ;
Olver, Stuart D. ;
Lor, Mary ;
Raffelt, Neil C. ;
Koyama, Motoko ;
Leveque, Lucie ;
Le Texier, Laetitia ;
Melino, Michelle ;
Markey, Kate A. ;
Varelias, Antiopi ;
Engwerda, Christian ;
Serody, Jonathan S. ;
Janela, Baptiste ;
Ginhoux, Florent ;
Clouston, Andrew D. ;
Blazar, Bruce R. ;
Hill, Geoffrey R. ;
MacDonald, Kelli P. A. .
JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (10) :4266-4280
[2]   Increased BCR responsiveness in B cells from patients with chronic GVHD [J].
Allen, Jessica L. ;
Tata, Prasanthi V. ;
Fore, Matthew S. ;
Wooten, Jenna ;
Rudra, Sharmistha ;
Deal, Allison M. ;
Sharf, Andrew ;
Hoffert, Todd ;
Roehrs, Philip A. ;
Shea, Thomas C. ;
Serody, Jonathan S. ;
Richards, Kristy L. ;
Jagasia, Madan ;
Lee, Stephanie J. ;
Rizzieri, David ;
Horwitz, Mitchell E. ;
Chao, Nelson J. ;
Sarantopoulos, Stefanie .
BLOOD, 2014, 123 (13) :2108-2115
[3]  
[Anonymous], FDA approves belumosudil for chronic graft-versus-host disease
[4]  
[Anonymous], FDA expands ibrutinib indications to chronic GVHD
[5]  
[Anonymous], FDA APPROVES RUXOLIT
[6]   Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study [J].
Cutler, Corey ;
Lee, Stephanie J. ;
Arai, Sally ;
Rotta, Marcello ;
Zoghi, Behyar ;
Lazaryan, Aleksandr ;
Ramakrishnan, Aravind ;
DeFilipp, Zachariah ;
Salhotra, Amandeep ;
Chai-Ho, Wanxing ;
Mehta, Rohtesh ;
Wang, Trent ;
Arora, Mukta ;
Pusic, Iskra ;
Saad, Ayman ;
Shah, Nirav N. ;
Abhyankar, Sunil ;
Bachier, Carlos ;
Galvin, John ;
Im, Annie ;
Langston, Amelia ;
Liesveld, Jane ;
Juckett, Mark ;
Logan, Aaron ;
Schachter, Levanto ;
Alavi, Asif ;
Howard, Dianna ;
Waksal, Harlan W. ;
Ryan, John ;
Eiznhamer, David ;
Aggarwal, Sanjay K. ;
Ieyoub, Jonathan ;
Schueller, Olivier ;
Green, Laurie ;
Yang, Zhongming ;
Krenz, Heidi ;
Jagasia, Madan ;
Blazar, Bruce R. ;
Pavletic, Steven .
BLOOD, 2021, 138 (22) :2278-2289
[7]   Current Use of and Trends in Hematopoietic Cell Transplantation in the United States [J].
D'Souza, Anita ;
Fretham, Caitrin ;
Lee, Stephanie J. ;
Arora, Mukta ;
Brunner, Janet ;
Chhabra, Saurabh ;
Devine, Steven ;
Eapen, Mary ;
Hamadani, Mehdi ;
Hari, Parameswaran ;
Pasquini, Marcelo C. ;
Perez, Waleska ;
Phelan, Rachel A. ;
Riches, Marcie L. ;
Rizzo, J. Douglas ;
Saber, Wael ;
Shaw, Bronwen E. ;
Spellman, Stephen R. ;
Steinert, Patricia ;
Weisdorf, Daniel J. ;
Horowitz, Mary M. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (08) :E177-E182
[8]   National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report [J].
DeFilipp, Zachariah ;
Couriel, Daniel R. ;
Lazaryan, Aleksandr ;
Bhatt, Vijaya Raj ;
Buxbaum, Nataliya P. ;
Alousi, Amin M. ;
Olivieri, Attilio ;
Pulanic, Drazen ;
Halter, Joerg P. ;
Henderson, Lori A. ;
Zeiser, Robert ;
Gooley, Ted A. ;
MacDonald, Kelli P. A. ;
Wolff, Daniel ;
Schultz, Kirk R. ;
Paczesny, Sophie ;
Inamoto, Yoshihiro ;
Cutler, Corey S. ;
Kitko, Carrie L. ;
Pidala, Joseph A. ;
Lee, Stephanie J. ;
Socie, Gerard ;
Sarantopoulos, Stefanie ;
Pavletic, Steven Z. ;
Martin, Paul J. ;
Blazar, Bruce R. ;
Greinix, Hildegard T. .
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (09) :729-737
[9]   Ibrutinib treatment ameliorates murine chronic graft-versus-host disease [J].
Dubovsky, Jason A. ;
Flynn, Ryan ;
Du, Jing ;
Harrington, Bonnie K. ;
Zhong, Yiming ;
Kaffenberger, Benjamin ;
Yang, Carrie ;
Towns, William H. ;
Lehman, Amy ;
Johnson, Amy J. ;
Muthusamy, Natarajan ;
Devine, Steven M. ;
Jaglowski, Samantha ;
Serody, Jonathan S. ;
Murphy, William J. ;
Munn, David H. ;
Luznik, Leo ;
Hill, Geoffrey R. ;
Wong, Henry K. ;
MacDonald, Kelli K. P. ;
Maillard, Ivan ;
Koreth, John ;
Elias, Laurence ;
Cutler, Corey ;
Soiffer, Robert J. ;
Antin, Joseph H. ;
Ritz, Jerome ;
Panoskaltsis-Mortari, Angela ;
Byrd, John C. ;
Blazar, Bruce R. .
JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (11) :4867-4876
[10]   Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes [J].
Dubovsky, Jason A. ;
Beckwith, Kyle A. ;
Natarajan, Gayathri ;
Woyach, Jennifer A. ;
Jaglowski, Samantha ;
Zhong, Yiming ;
Hessler, Joshua D. ;
Liu, Ta-Ming ;
Chang, Betty Y. ;
Larkin, Karilyn M. ;
Stefanovski, Matthew R. ;
Chappell, Danielle L. ;
Frissora, Frank W. ;
Smith, Lisa L. ;
Smucker, Kelly A. ;
Flynn, Joseph M. ;
Jones, Jeffrey A. ;
Andritsos, Leslie A. ;
Maddocks, Kami ;
Lehman, Amy M. ;
Furman, Richard ;
Sharman, Jeff ;
Mishra, Anjali ;
Caligiuri, Michael A. ;
Satoskar, Abhay R. ;
Buggy, Joseph J. ;
Muthusamy, Natarajan ;
Johnson, Amy J. ;
Byrd, John C. .
BLOOD, 2013, 122 (15) :2539-2549